Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey

GPR40 (FFAR1) is a promising target for the managing type 2 diabetes (T2D). The most advanced GPR40 agonist TAK-875 exhibited satisfactory glucose-lowering effects in phase II and III studies. However, the phase III studies of TAK-875 revealed drug-induced liver injury (DILI). It is unknown whether...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2021-09, Vol.16 (9), p.e0257477
Hauptverfasser:	Bazydlo-Guzenda, Katarzyna, Buda, Pawel, Mach, Mateusz, Pieczykolan, Jerzy, Kozlowska, Izabela, Janiszewski, Michal, Drzazga, Ewa, Dominowski, Jakub, Ziolkowski, Hubert, Wieczorek, Maciej, Gad, Shayne Cox
Format:	Artikel
Sprache:	eng
Schlagworte:	Agonists Animals Benzofurans Bile Biocompatibility Biology and Life Sciences Chemical and Drug Induced Liver Injury - metabolism Clinical trials Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diagnosis Drug dosages Ethylenediaminetetraacetic acid Genetic aspects Glucose Haplorhini Health aspects Hepatocytes Hepatocytes - drug effects Hepatocytes - metabolism Hepatotoxicity Humans Industrial safety Liver Liver - drug effects Liver - metabolism Liver - pathology Macaca fascicularis Male Medicine and Health Sciences Metabolism Metabolites Mice Mitochondria Monkeys Oxidation Primates Rats Rats, Zucker Receptors, G-Protein-Coupled - agonists Receptors, G-Protein-Coupled - metabolism Respiration Sulfones - pharmacology Toxicity Toxicology Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!